Dexmethylphenidate Hydrochloride

MONDAY, Jan. 27, 2025 -- Adderall shortages have prompted doctors to switch kids with attention-deficit/hyperactivity disorder ( ADHD ) to other forms of stimulant medication. Adderall prescription fills for children and teens plunged after the U.S. Food and Drug Administration (FDA) announced a shortage of the drug in October 2022, researchers reported in a new study published today in the journal Pediatrics . But at the same time, prescriptions for other types of stimulant drugs used in ADHD treatment increased, according to study results. “Our findings suggest that the Adderall shortage did not cause many children to stop stimulant therapy altogether, but it did force some to switch to alternative stimulants,” lead investigator Sijia He , a researcher at the Susan B. Meister Child Health Evaluation and Research Center in the University of Michigan, said in a news release. It’s too soon to tell whether these alternative stimulants wound up being a good or bad thing for children with ADHD, He noted. “This would be potentially concerning if the switches may have resulted in worsened ADHD control,” He said. “We need more research to evaluate whether any switches led to adverse outcomes.” More than 11% of children will be diagnosed with ADHD at some point during their lives, and prescription stimulants are considered a first-line treatment when drugs are required, researchers said in background notes. Stimulants are the most widely used ADHD medication, according to the U.S. Centers for Disease Control and Prevention. As many as 80% of children have fewer ADHD symptoms when taking these meds. For the study, researchers analyzed trends in stimulant prescriptions among children between the ages of 5 and 17, using national data that captures 92% of U.S. prescriptions. Results showed that the monthly stimulant dispensing rate to children declined by nearly 19% in March 2020, at the start of the COVID-19 pandemic, compared to January 2017. After that, the rate slowly edged up every month until the Adderall shortage was announced in October 2022, researchers said. After that, dispensing rates for Adderall decreased while rates for a substitute drug called dexmethylphenidate ( Focalin ) rose, the study says. The rates of stimulant dispensing varied by age and sex, researchers found: The results among girls are consistent with prior research indicating that first-time ADHD diagnoses were more common in girls than boys during the pandemic, researchers said. “A potentially optimistic explanation of these findings is that they represent a decrease in underdiagnosis and undertreatment of ADHD in girls,” senior investigator Dr. Kao-Ping Chua , a researcher at the University of Michigan Health C.S. Mott Children's Hospital in Ann Arbor, said in a news release. “It’s also possible that symptoms of inattention in girls increased during the pandemic, increasing their need for stimulants,” Chua added. Adderall fell into shortage due to both production issues as well as an unanticipated demand for stimulants in the U.S., particularly among adults. “Our findings indirectly demonstrate how increased demand for a medication class in adults may adversely affect access to these treatments for children,” Chua said. “It’s crucial to address the shortage of stimulant medications because so many kids rely on them,” he concluded. “Untreated ADHD symptoms can harm children’s health and learning.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 PART 01 周报概述 随着全球医药行业的快速发展，新药研发与创新已成为推动行业进步的重要动力。近期，根据摩熵数据统计，新药申请与审批活动频繁，显示出医药创新领域的活跃态势。 本文将深入分析2025年1月13日至2025年1月19日期间，国内外新药申请、临床试验批准以及仿制药一致性评价等多个方面的最新进展，为用户提供全面的行业资讯。 PART 02 国内33款新药IND获批 根据摩熵数据统计，2025年1月13日至2025年01月19日期间，共有80个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号60个，进口药品受理号20个。 本周共计33款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药22款，生物药9款，中药2款。 本周获批临床创新药/改良型新药（部分）信息速览(不含补充申请) 注：完整数据可识别“文末”二维码下载查看 PART 03 本周全球TOP10创新药研发进展 在全球创新药研发领域，1月13日，强生宣布厄达替尼片上市申请已正式获NMPA批准，用于治疗携带易感型FGFR3基因变异，且既往接受至少一线含抗PD-1或抗PD-L1期间或之后出现疾病进展的手术不可切除的局部晚期或转移性尿路上皮癌（UC）成人患者。同日，NMPA官网最新公示，上海生物制品研究所申报的贝伐珠单抗注射液生物类似药上市申请已正式获批。贝伐珠单抗是一款抗血管内皮生长因子（VEGF）人源化单克隆抗体。贝伐珠单抗能与人血管内皮生长因子VEGF特异性结合，通过阻断VEGF与其受体作用，进而抑制肿瘤新生血管的形成，抑制肿瘤生长转移。此外，和黄医药、第一三共、强生等药企取得新进展。 本周全球 TOP10 创新药研发进展截图来源：摩熵咨询周报 PART 04 50个品种过评，广州一品红制药等2家药企领跑 根据摩熵数据统计，2025年1月13日至2025年1月19日期间，共有99项仿制药申报上市/申报临床获CDE承办，其中新注册分类上市申请受理号96项（包括化药3类，4类，5.2类），新注册分类临床申请受理号3项（包括化药3类），本周一致性评价申请受理号7项；本周7个品种通过一致性评价（按受理号计11项），本周43个品种视同通过一致性评价（按受理号计59项）。本周无生物类似物注册申报动态。 本周过评/视同过评品种主要为血液和造血系统药物，过评/视同过评产品剂型主要为片剂；本周罗沙司他胶囊过评/视同过评受理号数量最多有5个，同时罗沙司他胶囊也是本周过评/视同过评企业数最多的品种有3家。 截图来源：摩熵咨询周报 在企业层面，本周河北天成药业股份有限公司、广州一品红制药有限公司和海南斯达制药有限公司等过评/视同过评品种数最多有2种，其余各企业过评/视同过评品种数紧随其后，本周过评/视同过评企业共包括河北天成药业股份有限公司、广州一品红制药有限公司和海南斯达制药有限公司等52家企业。 截图来源：摩熵咨询周报 本周有马来酸咪达唑仑片、盐酸右哌甲酯缓释胶囊2个品种首次过评/视同过评。 本周首次过评/视同过评品种截图来源：摩熵咨询周报 本周有奥美拉唑碳酸氢钠干混悬剂(Ⅰ)、复方甘草酸苷片、甲苯磺酸艾多沙班片3款过评/视同过评达 5 家企业品种。 此外，在全球TOP 10临床结果中，1 月 13 日，Corvus 公布了随机、双盲、安慰剂对照 1 期临床试验的新中期数据，该试验评估了 soquelitinib在中度至重度特应性皮炎患者中的作用。 本周全球 TOP10 积极/失败临床结果 同日，上海市胸科医院陆舜教授牵头全国 54 家研究中心共同参与的一项重组全人抗 PD-L1 单克隆抗体注射液（索卡佐利单抗）或安慰剂联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌的随机、双盲、安慰剂对照、多中心的 III 期临床研究发布阳性结果。 摩熵咨询本期完整周报 识别二维码领取下载 END 本文为原创文章，转载请留言获取授权  近期热门资源获取 后台回复关键词“深度报告”，获取价值18600元，报告大礼包 后台回复关键词“2023首仿”，获取2023年首仿药物获批名单 后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。 后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。 后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。 后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。 后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。 后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。 后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。 联系我们，体验摩熵医药更多专业服务 会议 合作 园区 服务 数据库 咨询 定制 服务 媒体 合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询 点击阅读原文，申请摩熵医药企业版免费试用！